4.2 Article

New β-Lactamase Inhibitors in the Clinic

期刊

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2016.02.007

关键词

beta- Lactamases; Inhibitor; Diazabicyclooctanones; Boronic acids; Sulfones; Monobactams; Carbapenems; Metallo-beta-lactamases

资金

  1. Cleveland Department of Veterans Affairs
  2. Veterans Affairs Career Development Program
  3. Veterans Affairs Merit Review Program Award [1I01BX002872, 1I01BX001974]
  4. Geriatric Research Education and Clinical Center VISN 10
  5. Harrington Foundation
  6. National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01 AI100560, R01 AI063517]

向作者/读者索取更多资源

Given the serious medical burden of beta-lactamases, many approaches are being used to identify candidate agents for beta-lactamase inhibition. Here, we review two beta-lactam-beta-lactamase inhibitor (BL-BLI) combinations, ceftolozane-tazobactam and ceftazidime-avibactam that recently entered the clinic. In addition, we focus on BL-BLI combinations in preclinical development that have demonstrated activity in clinical isolates via susceptibility testing and/or in in vivo models of infection. We highlight only the BLIs that are able to reduce the Clinical Laboratory Standards Institute (CLSI) breakpoints for the BL partner into the susceptible range. Our analysis includes the primary literature, meeting abstracts, as well as the patent literature.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据